Skip to main content
Clinical Trials/ISRCTN10640292
ISRCTN10640292
Active, not recruiting
未知

Safety and effectiveness clinical evaluation of injectable medical device Hydragel A1 in the skin quality improvement

ouna Aesthetics0 sites40 target enrollmentMay 2, 2023

Overview

Phase
未知
Intervention
Not specified
Conditions
Patient seeking aesthetic treatment of the facial skin quality such as skin elasticity or firmness and facial skin radiance
Sponsor
ouna Aesthetics
Enrollment
40
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 2, 2023
End Date
January 25, 2024
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
ouna Aesthetics

Eligibility Criteria

Inclusion Criteria

  • 1\. Female and male subjects
  • 2\.Fitzpatrick skin of the face from III to V
  • 3\. Aged between 18 to 45 years old
  • 4\. Subjects seeking an improvement in their skin brightness
  • 5\. Subjects seeking improvement of their skin quality
  • 6\. Subjects of any phototype and ethnicity
  • 7\. Subjects who have given their consent for photographs for illustration purposes
  • 8\. Subjects willing to abstain from other facial aesthetic procedures in the mid\-face through the entire study duration
  • 9\. Subjects in good general and mental health in the opinion of the investigator
  • 10\. Subjects who have given their free, informed and expressed written consent

Exclusion Criteria

  • 1\. Subject with any systemic disorder or skin disease that would in any way confound the interpretation of the study results
  • 2\. Subjects with medical/surgical/severe allergy/anaphylactic shock history that, in the opinion of the Investigator, could compromise the safety of the subject or affect the outcome of the study
  • 3\. Subjects having a known risk of hypersensitivity to one of the components of the composition
  • 4\. Subjects suffering from autoimmune disease
  • 5\. Subjects having cutaneous disorders, inflammation or infection (herpes, acne, etc.) at the treatment site or nearby
  • 6\. Subjects for whom medical history shows a sensitivity that could lead to a reaction to the treatment
  • 7\. Subjects with bleeding disorders or subjects who are undergoing treatment with thrombolytics or anticoagulants
  • 8\. Subjects with a tendency to form keloids, hypertrophic scars or any other healing disorders
  • 9\. Subjects who are currently following a skin treatment
  • 10\. Pregnant or breastfeeding women or those considering a pregnancy during the study

Outcomes

Primary Outcomes

Not specified

Similar Trials